延长输注β-内酰胺类抗生素国际共识建议
该国际共识由多学科专家小组制定,获ACCP、BSAC、CFF、ESCMID、IDSA、SCCM和SIDP认可,针对延长输注(含持续输注)β-内酰胺类抗生素提供治疗建议。共识涵盖药动学/药效学目标、治疗药物监测考虑,以及重症与非重症成人、儿科和肥胖患者的应用推荐。
要点
- β-内酰胺类呈时间依赖性杀菌,延长输注可增加血药浓度高于MIC的时间。
- 共识推荐涉及药动学/药效学靶值及治疗药物监测的具体考虑。
- 推荐覆盖重症与非重症成人、儿科及肥胖患者的延长输注应用。
核心结论
- 该共识为延长输注β-内酰胺类抗生素的临床应用提供了首个国际共识指导。
研究设计与样本
- 由临床药学与医学专家组成的国际专家小组制定共识治疗推荐,并获ACCP、BSAC、CFF、ESCMID、IDSA、SCCM和SIDP认可。
主要发现
- β-内酰胺类具有时间依赖性杀菌活性,细菌负荷下降与给药间期内游离药物浓度高于病原体MIC的时间直接相关。
- 延长(含持续)输注可在静脉β-内酰胺类给药期间增加血药浓度高于MIC的时间。
- 延长输注给药方案已在全球实施,但实施情况不一致。
关键数值与推荐
- 共识推荐涉及药动学/药效学靶值、治疗药物监测考虑以及延长输注β-内酰胺类在特定患者人群中的应用。
临床怎么用
- 临床可参照该共识,在重症与非重症成人、儿科及肥胖患者中规范实施延长输注β-内酰胺类治疗。
局限性
- 原文未报告共识制定中检索或证据评价的具体方法细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intravenous β-lactam antibiotics remain a cornerstone in the management of bacterial infections due to their broad spectrum of activity and excellent tolerability. β-lactams are well established to display time-dependent bactericidal activity, where reductions in bacterial burden are directly associated with the time that free drug concentrations remain above the minimum inhibitory concentration (MIC) of the pathogen during the dosing interval. In an effort to take advantage of these bactericidal characteristics, prolonged (extended and continuous) infusions (PIs) can be applied during the administration of intravenous β-lactams to increase time above the MIC. PI dosing regimens have been implemented worldwide, but implementation is inconsistent. We report consensus therapeutic recommendations for the use of PI β-lactams developed by an expert international panel with representation from clinical pharmacy and medicine. This consensus guideline provides recommendations regarding pharmacokinetic and pharmacodynamic targets, therapeutic drug-monitoring considerations, and the use of PI β-lactam therapy in the following patient populations: severely ill and nonseverely ill adult patients, pediatric patients, and obese patients. These recommendations provide the first consensus guidance for the use of β-lactam therapy administered as PIs and have been reviewed and endorsed by the American College of Clinical Pharmacy (ACCP), the British Society for Antimicrobial Chemotherapy (BSAC), the Cystic Fibrosis Foundation (CFF), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), the Infectious Diseases Society of America (IDSA), the Society of Critical Care Medicine (SCCM), and the Society of Infectious Diseases Pharmacists (SIDP).
引用
- Hong LT, Downes KJ, FakhriRavari A, et al. International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2023. PMID: 37615245. doi:10.1002/phar.2842
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。